Sotera Health Company - SHC STOCK NEWS

Sotera Health Company (Nasdaq: SHC) reported Q1 2021 net revenues of $212 million, up 13% from Q1 2020. The company posted a net income of $11 million or $0.04 per diluted share, reversing the $2 million loss in the same quarter last year. Adjusted EBITDA rose 15% to $105 million, and Adjusted EPS increased 80% to $0.18. The total debt stood at $1.87 billion, with a net leverage ratio of 4.1x. Sotera Health reaffirmed its 2021 outlook, expecting net revenues between $890 million and $920 million.

Sotera Health Company (Nasdaq: SHC) will release its financial results for Q1 2021 on May 13, 2021, before market open. A conference call is scheduled for 9:00 a.m. ET to discuss operating highlights and results. Interested participants can join by dialing 1-833-303-1211 (US/Canada) or 1-918-922-6527 (international). Sotera Health will also present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 8:00 a.m. ET. The company is recognized for its end-to-end sterilization solutions and lab testing services, supporting healthcare globally.

Sotera Health Company (Nasdaq: SHC) announced the pricing of its secondary offering of 25,000,000 shares at $27.00 per share, with selling stockholders, including affiliates of Warburg Pincus LLC and GTCR, LLC. The offering will not raise funds for the company, which will not receive any proceeds. A 30-day option for underwriters to purchase an additional 3,750,000 shares is included. The offering closes on March 22, 2021, subject to conditions. Key underwriters include J.P. Morgan, Credit Suisse, and Goldman Sachs.

Sotera Health Company announced a secondary offering of 25,000,000 shares of its common stock, aimed exclusively at selling stockholders, including affiliates of Warburg Pincus LLC and GTCR, LLC. The offering allows underwriters a 30-day option to purchase an additional 3,750,000 shares. Notably, Sotera will not receive any proceeds from this offering. The company is also seeking an amendment to its credit agreement to improve terms and extend maturity on its undrawn revolving credit facility, although success is uncertain due to varying market conditions.

Sterigenics S.A.S., a Sotera Health subsidiary, is expanding its ethylene oxide sterilization facility in Rantigny, France, to enhance sterilization capacity and capability. This expansion addresses increased local and regional demand for contract sterilization services in the healthcare sector. The facility will now include a 32-pallet chamber, improving throughput and flexibility for customers. This development follows Sterigenics' recent acquisition of Iotron Industries, further diversifying sterilization technologies and enhancing global service offerings.

Sotera Health Company (Nasdaq: SHC) reported Q4 2020 net revenues of $217 million, a 12% increase year-over-year. However, the Q4 net loss was $44 million, up from a $28 million loss in Q4 2019, factoring in significant debt extinguishment costs. Adjusted EBITDA rose 20% to $113 million, and Adjusted EPS improved to $0.09. For 2021, Sotera projects revenues of $890 million to $920 million (growth of 9% to 12%) and Adjusted EBITDA of $465 million to $485 million (growth of 11% to 16%).

Sotera Health Company (Nasdaq: SHC) announced that its CFO, Scott Leffler, will present at the Citi 2021 Healthcare Services Conference on February 24, 2021, at 8:00 am ET. Additionally, CEO Michael B. Petras, Jr. will present at the Barclays Global Healthcare Conference on March 10, 2021, at 9:10 am ET. Investors can access both live and archived webcasts via the Sotera Health website. Sotera Health specializes in end-to-end sterilization solutions and lab testing services and is committed to its mission of Safeguarding Global Health.

Sotera Health Company (Nasdaq: SHC) announced the successful amendment and repricing of its First Lien Term Loan, reducing the interest rate spread from 450 to 275 basis points and the LIBOR floor from 100 to 50 basis points. This results in a 2.25% decrease in effective interest rates, leading to expected annual cash interest savings of approximately $40 million. The repricing aims to improve liquidity and support strategic investments, despite potential offsetting charges from the amendment.

Sotera Health Company (Nasdaq: SHC) announced preliminary results for the fourth quarter and full year 2020, expecting revenues of approximately $216 million and $817 million respectively, reflecting an annual growth rate of 5%. The company highlighted its strategic acquisition, capacity investments, and successful IPO as pivotal moves during a challenging pandemic year. Pro forma revenue estimates suggest a full-year total of $832 million when accounting for pre-acquisition contributions. The company is scheduled to present at the J.P. Morgan Healthcare Conference today and will release detailed earnings on March 9, 2021.